Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
How To Allocate $100,000 In A Dividend Portfolio: A Strategic Guide For Income And Growth
09:00am, Thursday, 22'nd Aug 2024
I will demonstrate how you could allocate the amount of $100,000 by following the current composition of The Dividend Income Accelerator Portfolio, effectively balancing dividend income and dividend g
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
06:17am, Thursday, 22'nd Aug 2024
Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
06:45pm, Wednesday, 21'st Aug 2024
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
11:31am, Wednesday, 21'st Aug 2024
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million.
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
11:31am, Wednesday, 21'st Aug 2024
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
J&J Gets FDA Approval of New Chemo-Free Lung Cancer Treatment
04:51pm, Tuesday, 20'th Aug 2024
Johnson & Johnson (JNJ) on Tuesday announced Food and Drug Administration (FDA) approval of a two-drug, chemotherapy-free treatment plan for certain types of lung cancer, along with an acquisition exp
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
10:06am, Tuesday, 20'th Aug 2024
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion
08:41am, Tuesday, 20'th Aug 2024
The FDA has approved Rybrevant plus Lazcluze in the U.S. for the treatment of patients with non-small cell lung cancer.
J&J to acquire V-Wave for up to $1.7 billion in play for heart failure device
07:55am, Tuesday, 20'th Aug 2024
Johnson & Johnson JNJ said Tuesday it has agreed to acquire V-Wave Ltd., a privately held company developing treatments for patients with heart failure, for $600 million upfront and potential extra pa
J&J to buy medical device maker V-Wave in up to $1.1 bln deal
07:46am, Tuesday, 20'th Aug 2024
Johnson & Johnson said on Tuesday it would buy medical device maker V-Wave in a deal potentially worth up to $1.1 billion, marking the latest acquisition to bolster its devices unit.
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt
07:45am, Tuesday, 20'th Aug 2024
The stock market is dynamic, often characterized by periods of volatility and uncertainty. These periods can be particularly challenging for investors susceptible to the pervasive influence of Fear, U
Johnson & Johnson to Acquire V-Wave
07:30am, Tuesday, 20'th Aug 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on develop
US FDA approves J&J's combination therapy for type of lung cancer
07:17am, Tuesday, 20'th Aug 2024
The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.
Johnson & Johnson wins first FDA approval for chemotherapy-free lung cancer treatment
07:12am, Tuesday, 20'th Aug 2024
Johnson & Johnson JNJ, +0.15% said Tuesday the U.S. Food and Drug Administration has approved a combination treatment for a type of lung cancer that's the first chemotherapy-free regimen. The FDA has
RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIP
